Literature DB >> 8139760

Binding characteristics of [3H]flunitrazepam in pentobarbital-withdrawal rats.

T Miyaoka1, T Kimura, P A Saunders, Y T Tseng, I K Ho.   

Abstract

The effects of chronic pentobarbital (PB) treatment on the binding characteristics of [3H]flunitrazepam (FLU) in rat brain were examined. Saline or sodium PB (500 micrograms/10 microliters/hr) was infused into the lateral cerebral ventricles of rats for 6 days using osmotic pumps. Immediately before withdrawal, there were no significant differences in [3H]FLU binding constants (KD and Bmax) between saline and PB groups. However, 24 hr withdrawal caused an increase in Bmax with no changes in KD. The enhancement of [3H]FLU binding by in vitro addition of chloride ions and PB was not affected after the PB infusion. The PB enhancement of [3H]FLU binding was inhibited by the convulsant, picrotoxinin. PB withdrawal did not cause significant differences in the binding constants of [3H]Ro 15-1788, a benzodiazepine (BZ) antagonist, between the saline and PB groups. Pretreatment of membranes with 0.02 mM of 3-[(3-cholamidopropyl)-dimethylammonio]-1- propanesulfonate (CHAPS), a zwitterionic detergent, caused decreases in both KD and Bmax in FLU binding in PB-withdrawal membrane, but not in the saline-treated membrane. The enhancement of [3H]FLU binding by chloride ions and PB was not affected by the CHAPS treatment. These results suggest that the change in BZ receptors induced by PB withdrawal is functionally linked to the GABA-BZ-barbiturate receptor complex and that PB withdrawal induces some conformational changes in BZ receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8139760     DOI: 10.1007/bf00966726

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  26 in total

1.  [3H]muscimol and [3H]quinuclidinyl benzilate binding in rat cortex in the abstinence after long-term barbital treatment.

Authors:  A Nordberg; G Wahlström; B Eriksson
Journal:  Acta Physiol Scand       Date:  1986-01

Review 2.  GABA-benzodiazepine-barbiturate receptor interactions.

Authors:  R W Olsen
Journal:  J Neurochem       Date:  1981-07       Impact factor: 5.372

3.  Interaction of depressant, convulsant, and anticonvulsant barbiturates with the [3H]diazepam binding site of the benzodiazepine-GABA-receptor-ionophore complex.

Authors:  M K Ticku
Journal:  Biochem Pharmacol       Date:  1981-06-15       Impact factor: 5.858

4.  A nondenaturing zwitterionic detergent for membrane biochemistry: design and synthesis.

Authors:  L M Hjelmeland
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

5.  Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system.

Authors:  S R Zukin; A B Young; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1974-12       Impact factor: 11.205

6.  Induction of tolerance to and physical dependence on pentobarbital continuous intracerebroventricular administration.

Authors:  T Kimura; T Miyaoka; P A Saunders; M L Baker; A S Hume; I Yamamoto; I K Ho
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

7.  Evidence for GABA tolerance in barbiturate-dependent and withdrawn mice.

Authors:  P L Gray; P V Taberner
Journal:  Neuropharmacology       Date:  1985-05       Impact factor: 5.250

8.  Binding characteristics of 3H-flunitrazepam and CL-218,872 in cerebellum and cortex of C57B1 mice made tolerant to and dependent on phenobarbital or ethanol.

Authors:  S Liljequist; B Tabakoff
Journal:  Alcohol       Date:  1985 Mar-Apr       Impact factor: 2.405

9.  Barbiturate receptor sites are coupled to benzodiazepine receptors.

Authors:  F Leeb-Lundberg; A Snowman; R W Olsen
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

10.  Pentobarbital tolerance and withdrawal: correlation with effects on the GABAA receptor.

Authors:  P A Saunders; Y Ito; M L Baker; A S Hume; I K Ho
Journal:  Pharmacol Biochem Behav       Date:  1990-10       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.